gvtcx

Biosimilars and Biologics

The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Statuscomplete
Category (CPV) 33600000
RegionWales
Deadline1 Mar 2021
Procedureopen
OCIDocds-h6vhtk-028d8b

Awards (18)

This procurement was awarded to 18 suppliers. Values shown are per-award; the notice total is ·.

SupplierValueDateStatus
Abbvie Ltd shared · · active
Alcura UK Ltd shared · · active
Amgen Ltd shared · · active
Biogen Idec Ltd shared · · active
Celltrion Healthcare UK Ltd shared · · active
Eli Lilly & Company Ltd shared · · active
Fresenius Kabi Ltd shared · · active
Gedeon Richter shared · · active
Healthcare at Home shared · · active
Merck Sharp & Dohme shared · · active
Napp Pharmaceutical Group Ltd shared · · active
Organon Pharma (UK) Limited shared · · active
Pfizer Limited shared · · active
Roche Products Ltd shared · · active
Sandoz Ltd shared · · active
Teva UK Ltd shared · · active
Thornton & Ross Ltd shared · · active
Zentiva Pharma UK Ltd shared · · active

description

Biosimilars and Biologics

notice history

2 notices published against this procurement.

PublishedTypeRegimeNotice
26 Jan 2021 Contract notice (F02) Earlier regulations 001589-2021
26 Jul 2021 Contract award notice (F03) Earlier regulations 017732-2021

more from Velindre NHS Trust, NHS Wales Shared Services Partnership - Procurement Services (on behalf of All Wales UHBs & Trusts

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Find a Tender. Contact details for named individuals are not reproduced on this site.